$7.70 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Immunovant

Immunovant, Inc., formerly Health Sciences Acquisitions Corp, is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. It is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn).

Stock Analysis

last close $7.55
1-mo return -6.1%
3-mo return -10.1%
avg daily vol. 530.08T
52-week high 53.61
52-week low 6.68
market cap. $894M
forward pe -
annual div. -
roe -35.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 29.9%

Subscribe now for daily local and international financial news